arrow_back Back Filing freshness 10-Q Q2 FY2026 SEC EDGAR

Profound Medical Corp.

PROF
$6.85 ▼ -0.30 (-4.20%) at close
Healthcare ·Surgical & Medical Instruments & Apparatus ·USSurgical & Medical Instruments & Apparatus
16 Visible periods
29 Metrics
Peer-ranked Benchmarks
Price Chart
24
Health
Poor
Moderately Bearish
auto_awesome

Analytical Summary

Profound Medical Corp. faces fundamental challenges with weakness in Return on Common Equity (%). On the positive side, Debt to Equity remains strong. Investors should exercise caution and monitor for improvement in key metrics.

Market Cap $249.0M
Dividend Yield —
Revenue Growth 12.3% ↘
Op. Margin -445.7% ↘
ROIC -20.5% ↘
FCF / Share $-0.31 ↘
Trailing P/E —
Price / Book 5.0x
FCF Yield —
Debt / Equity 0.09
info Valuation on last close. End-of-day price, Nov 5, 2026.

16-Year Financial Trajectory

Quarterly
Metric Value Trend Year over Year Percentile
Revenue Total top-line sales
$2.48M
↑ +12.3% —
Net Income Profit after all expenses
$-7.05M
↑ +34.2% —
Operating Margin Operating profit as % of sales
-445.7%
↓ -196.5% 0th
FCF / Share Free cash flow per share
$-0.31
↓ -31.9% —
Long-Term Debt Long-term obligations
$4.51M
— +0.1% —
trending_up

Bullish Indicators

  • Debt to EquityDebt to Equity is in the top quartile (lower is better)
warning

Bearish Risks

  • Operating Margin (%)Operating Margin (%) is in the bottom quartile
  • Profit Margin (%)Profit Margin (%) is in the bottom quartile
  • Return on Common Equity (%)Return on Common Equity (%) is in the bottom quartile

Health Breakdown

Profitability ↑
1
Returns ↑
14
Financial Health ↓
49
Cash Quality ↑
60

bar_chart Data from SEC EDGAR XBRL filings

Synced 4 days ago 8 years · 16 quarters